Search

Your search keyword '"Fukuo Y"' showing total 3 results
Start Over Author "Fukuo Y" Journal journal of affective disorders
3 results on '"Fukuo Y"'

1. GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder

Author

Kishi, T., Ichinose, Hiroshi, Yoshimura, R., Fukuo, Y., Kitajima, T., Inada, T., Kunugi, H., Kato, T., Yoshikawa, T., Ujike, H., Musso, G.M., Umene-Nakano, W., Nakamura, J., Ozaki, N., and Iwata, N.

Subjects
Oncology, Adult, Male, Candidate gene, medicine.medical_specialty, Bipolar Disorder, Genotype, behavioral disciplines and activities, Polymorphism, Single Nucleotide, Asian People, Gene Frequency, Internal medicine, mental disorders, Genetic model, medicine, Humans, Bipolar disorder, GTP Cyclohydrolase, Allele frequency, Genetics, Depressive Disorder, Major, Case-control study, Hamilton Rating Scale for Depression, Middle Aged, medicine.disease, Antidepressive Agents, Psychiatry and Mental health, Clinical Psychology, Logistic Models, Phenotype, Mood disorders, Haplotypes, Fluvoxamine, Case-Control Studies, Major depressive disorder, Female, Psychology, Selective Serotonin Reuptake Inhibitors
Abstract

Background Tetrahydrobiopterin (BH4) plays an important role in the biosynthesis of serotonin, melatonin and catecholamines, all of which are implicated in the pathophysiology of mood disorders (MDs), including major depressive disorder (MDD) and bipolar disorder (BP). Production of BH4 is regulated by GTP cyclohydrolase transcription and activity. Thus, we considered the GTP cyclohydrolase gene ( GCH1 ) to be a good candidate gene in the pathophysiology of MDs and of the serotonin selective reuptake inhibitors (SSRIs) response in MDD, and conducted a case-control study utilizing three SNPs (rs8007267, rs3783641 and rs841) and moderate sample sizes (405 MDD patients, including 262 patients treated by SSRIs, 1022 BP patients and 1805 controls). Method A multiple logistic regression analysis was carried out to compare the frequencies of each SNP genotype for the target phenotype across patients and controls in several genetic models, while adjusting for possible confounding factors. A clinical response was defined as a decrease of more than 50% from the baseline score on the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D) within 8 weeks, and clinical remission as a SIGH-D score of less than 7 at 8 weeks. Result No associations between three SNPs in GCH1 and MDD or BP were observed; however, GCH1 was associated with SSRI therapeutic response in MDD in all the marker’s haplotype analysis (Global P value=0.0379). Conclusions Results suggest that GCH1 may predict response to SSRI in MDD in the Japanese population. Nevertheless, a replication study using larger samples may be required for conclusive results, since our sample size was small.

Published
2012

2. Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population.

Author

Fukuo Y, Kishi T, Kushima I, Yoshimura R, Okochi T, Kitajima T, Matsunaga S, Kawashima K, Umene-Nakano W, Naitoh H, Inada T, Nakamura J, Ozaki N, and Iwata N

Subjects
Adult, Asian People genetics, Case-Control Studies, Circadian Clocks, Depressive Disorder, Major ethnology, Female, Fluvoxamine therapeutic use, Genetic Predisposition to Disease, Genotype, Haplotypes, Humans, Male, Paroxetine therapeutic use, Polymorphism, Single Nucleotide, Psychiatric Status Rating Scales, Selective Serotonin Reuptake Inhibitors therapeutic use, Sertraline therapeutic use, Treatment Outcome, Ubiquitin genetics, Ubiquitin therapeutic use, Depressive Disorder, Major drug therapy, Depressive Disorder, Major genetics, Endopeptidases genetics
Abstract

Background: Several investigations have reported that abnormalities in circadian rhythms might be related to the pathophysiology of major depressive disorder (MDD) and the therapeutic response to selective serotonin reuptake inhibitors (SSRIs). Recently, ubiquitin-specific peptidase 46 (USP46), a new molecule related to the circadian clock system, has been described. We conducted a case control study between seven tagging SNPs (rs10517263, rs17675844, rs6554557, rs12646800, rs2244291, rs10034164, rs346005) in the USP46 gene, MDD, and the SSRI therapeutic response in MDD in the Japanese population., Method: We recruited 432 MDD patients (202 males and 230 females) and 792 healthy controls (319 males and 473 females). Two hundred sixty-one of 432 MDD patients were treated with SSRIs (fluvoxamine, sertraline or paroxetine)., Result: We detected an association between the USP46 gene and MDD in a haplotype analysis (rs2244291-rs10034164-rs346005 and rs12646800-rs2244291-rs10034164-rs346005). However, we did not find any association between the USP46 gene and SSRI response or remission in MDD in the Japanese population., Limitations: A replication study using larger samples may be required for conclusive results, since our sample size was small., Conclusions: Our results suggest that the USP46 gene might play a role in the pathophysiology of MDD in the Japanese population., (Crown Copyright © 2011. Published by Elsevier B.V. All rights reserved.)

Published
2011
Full Text
View/download PDF

3. SIRT1 gene is associated with major depressive disorder in the Japanese population.

Author

Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Fukuo Y, Naitoh H, Umene-Nakano W, Inada T, Nakamura J, Ozaki N, and Iwata N

Subjects
Alleles, Depressive Disorder, Major drug therapy, Female, Genetic Association Studies, Genotype, Haplotypes genetics, Humans, Japan, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Psychiatric Status Rating Scales, Selective Serotonin Reuptake Inhibitors therapeutic use, Treatment Outcome, Depressive Disorder, Major genetics, Sirtuin 1 genetics
Abstract

Background: Many studies including our previous ones as to PROKR2 and CLOCK have suggested that circadian genes may be involved in the mechanisms of mood disorders and their treatment responses. Also several recent investigations have reported that SIRT1 plays an important role in the circadian system as conventional circadian clock genes, and also have some relation to dopaminergic metabolism. So we considered the SIRT1 gene to be a good candidate gene for the pathophysiology for MDD and SSRI responses in MDD, and conducted a case-control study using four tagging SNPs (450 MDD patients, including 261 patients treated by SSRIs and 766 controls)., Method: The MDD patients in this study had scores of 12 or higher on the 17 items of the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D). We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks, and clinical remission as an SIGH-D score of less than 7 at 8 weeks. Marker-trait association analysis was used to evaluate allele and genotype association with the chi-square test, and haplotype association analysis was evaluated with a likelihood ratio test., Result: We found an association between rs10997875 in SIRT1 gene and MDD in the allele/genotype analysis. In addition, this significance of these associations survived Bonferroni correction. However, we did not find any association between SIRT1 gene and SSRI therapeutic response in MDD in the allele/genotype analysis or haplotype analysis., Limitations: A replication study using larger samples may be required for conclusive results, since our sample size was small., Conclusions: Our results suggest that rs10997875 in SIRT1 gene may play a role in the pathophysiology of MDD in the Japanese population., (Copyright 2010 Elsevier B.V. All rights reserved.)

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results